Simcere Pharma Buys Back 1.97 Million Shares, Brings Cumulative Repurchases to 12.83 Million

Bulletin Express03-26

Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444 and HKD 11.3272, for a total consideration of HKD 22.03 million.

The latest buyback represents 0.08% of Simcere Pharma’s issued share capital of approximately 2.60 billion shares. All repurchased shares are intended for cancellation.

Including previous repurchases on 12 January, 16 January, 20 January and 22 January, the company has bought back 12.83 million shares under its current mandate, equivalent to 0.52% of the shares outstanding when the mandate was approved on 13 June 2025. The mandate authorises Simcere Pharma to repurchase up to 247.47 million shares.

No new shares were issued during the period, leaving the company’s issued share count unchanged at about 2.60 billion. A 30-day moratorium on new share issues or treasury-share sales is in effect until 25 April 2026, in accordance with Hong Kong Stock Exchange regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116060338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116060338","market":"us","top_or_hot":-1,"title":"Simcere Pharma Buys Back 1.97 Million Shares, Brings Cumulative Repurchases to 12.83 Million","media":"Bulletin Express","content":"<p>Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444 and HKD 11.3272, for a total consideration of HKD 22.03 million.</p>\n<p>The latest buyback represents 0.08% of Simcere Pharma’s issued share capital of approximately 2.60 billion shares. All repurchased shares are intended for cancellation.</p>\n<p>Including previous repurchases on 12 January, 16 January, 20 January and 22 January, the company has bought back 12.83 million shares under its current mandate, equivalent to 0.52% of the shares outstanding when the mandate was approved on 13 June 2025. The mandate authorises Simcere Pharma to repurchase up to 247.47 million shares.</p>\n<p>No new shares were issued during the period, leaving the company’s issued share count unchanged at about 2.60 billion. A 30-day moratorium on new share issues or treasury-share sales is in effect until 25 April 2026, in accordance with Hong Kong Stock Exchange regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharma Buys Back 1.97 Million Shares, Brings Cumulative Repurchases to 12.83 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharma Buys Back 1.97 Million Shares, Brings Cumulative Repurchases to 12.83 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-26 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444 and HKD 11.3272, for a total consideration of HKD 22.03 million.</p>\n<p>The latest buyback represents 0.08% of Simcere Pharma’s issued share capital of approximately 2.60 billion shares. All repurchased shares are intended for cancellation.</p>\n<p>Including previous repurchases on 12 January, 16 January, 20 January and 22 January, the company has bought back 12.83 million shares under its current mandate, equivalent to 0.52% of the shares outstanding when the mandate was approved on 13 June 2025. The mandate authorises Simcere Pharma to repurchase up to 247.47 million shares.</p>\n<p>No new shares were issued during the period, leaving the company’s issued share count unchanged at about 2.60 billion. A 30-day moratorium on new share issues or treasury-share sales is in effect until 25 April 2026, in accordance with Hong Kong Stock Exchange regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1116060338","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116060338","pubTimestamp":1774526735,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声药业回购197万股累计回购1283万","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444 and HKD 11.3272, for a total consideration of HKD 22.03 million.\nThe latest buyback represents 0.08% of Simcere Pharma’s issued share capital of approximately 2.60 billion shares. All repurchased shares are intended for cancellation.\nIncluding previous repurchases on 12 January, 16 January, 20 January and 22 January, the company has bought back 12.83 million shares under its current mandate, equivalent to 0.52% of the shares outstanding when the mandate was approved on 13 June 2025. The mandate authorises Simcere Pharma to repurchase up to 247.47 million shares.\nNo new shares were issued during the period, leaving the company’s issued share count unchanged at about 2.60 billion. A 30-day moratorium on new share issues or treasury-share sales is in effect until 25 April 2026, in accordance with Hong Kong Stock Exchange regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116060338","isCrawlerRequest":true}